In Brief: ImmuLogic
Executive Summary
ImmuLogic: Modifies Allervax CAT development program to include "at least one additional trial prior to a PLA submission," company says following meeting with FDA on Dec. 19. A Phase III trial evaluating a 750 mcg dose of Allervax CAT (peptide immunotherapeutic for treatment of allergies to cat dander) administered twice a week for two weeks is set to begin in the second quarter of 1997. That trial will focus on more severely allergic patients...
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth